V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

Edwards Lifesciences Executive Compensation (FY25)

EW · Irvine, CA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Bernard Zovighian
Median of the other named officers
$4,695,742
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 7, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Edwards Lifesciences brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 8, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Edwards Lifesciences brief$1,500Get the executive brief
Velarion Member, one year
433 figures on this page: 424 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bernard Zovighian: $14,579,474 → $17,454,255 (19.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Edwards Lifesciences' chief executive and what were they paid?
Bernard Zovighian was paid $17,454,255 in total compensation as Chief Executive Officer and Director for fiscal 2025. Zovighian's total moved 19.7% higher from the $14,579,474 reported for fiscal 2024.
What was Edwards Lifesciences' say-on-pay result?
The say-on-pay proposal drew 89.3% support at the meeting held May 7, 2026 for fiscal 2025.
Which companies are in Edwards Lifesciences' peer group?
The disclosed peer group includes Abbott Laboratories, Agilent Technologies, Inc., Align Technology, Inc., Baxter International Inc. and Becton, Dickinson and Company, among others.
What is Edwards Lifesciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 194:1, against median employee compensation of $89,827.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Mussallem
Chairman of the Board and Chief Executive Officer
◇—◇◇◇—◇◇
Jean-Luc Lemercier
Corporate Vice President
◇—◇◇◇—◇◇
Scott Ullem
Corporate Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Larry Wood
Corporate Vice President, Transcatheter Heart Valves
◇◇◇◇◇—◇◇
Bernard Zovighian
Corporate Vice President
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Zovighian
Chief Executive Officer
◇—◇◇◇—◇◇
Scott Ullem
Corporate Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Larry Wood
Corporate Vice President, Transcatheter Heart Valves
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Zovighian
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Catherine Szyman
Former Corporate Vice President, Critical Care
Departed during or after this year
◇◇◇—◇—◇◇
Scott Ullem
Corporate Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Larry Wood
Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart
◇—◇◇◇—◇◇
Jean-Luc Lemercier
Former Corporate Vice President, EMEACLA
Departed during or after this year
◇—◇◇◇—◇◇
Donald Bobo
Corporate Vice President, Strategy & Corporate Development
◇◇◇◇◇—◇◇
Daveen Chopra
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Zovighian
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Scott Ullem
Corporate Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Larry Wood
Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart
Departed during or after this year
◇—◇◇◇—◇◇
Daveen Chopra
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
◇—◇◇◇—◇◇
Donald Bobo
Corporate Vice President, Strategy & Corporate Development
◇—◇◇◇—◇◇
Annette Brüls
Corporate Vice President, EMEACLA
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Annette BrülsPSU◇—◇—◇—◇
Annette BrülsOPTION◇——◇—◇◇
Annette BrülsRSU◇——◇——◇
Bernard ZovighianOPTION◇——◇—◇◇
Bernard ZovighianPSU◇—◇—◇—◇
Bernard ZovighianRSU◇——◇——◇
Daveen ChopraOPTION◇——◇—◇◇
Daveen ChopraRSU◇——◇——◇
Daveen ChopraRSU◇——◇——◇
Daveen ChopraPSU◇—◇—◇—◇
Donald BoboPSU◇—◇—◇—◇
Donald BoboOPTION◇——◇—◇◇
Donald BoboRSU◇——◇——◇
Larry WoodOPTION◇——◇—◇◇
Larry WoodPSU◇—◇—◇—◇
Larry WoodRSU◇——◇——◇
Scott UllemPSU◇—◇—◇—◇
Scott UllemRSU◇——◇——◇
Scott UllemOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Annette BrülsRSU◇=——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇07/10/2031
Option◇—◇05/07/2032
Bernard ZovighianRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇05/06/2031
Option◇—◇05/02/2029
Option◇—◇05/10/2030
Option◇—◇05/07/2032
Scott UllemRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇05/02/2029
Option◇—◇05/10/2030
Option◇—◇05/06/2031
Option◇—◇05/07/2032
Daveen ChopraRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇05/02/2029
Option◇—◇05/10/2030
Option◇—◇05/06/2031
Option◇—◇05/07/2032
Donald BoboRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇05/07/2032
Option◇—◇05/10/2030
Option◇—◇05/06/2031
Larry WoodRSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Bernard Zovighian
Chief Executive Officer and Director · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Daveen Chopra
Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Donald Bobo
Corporate Vice President, Strategy & Corporate Development · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Larry Wood
Former Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart · Terms as described in the company’s compensation discussion · citing a 2026 filing
Excise tax treatment◇
Scott Ullem
Corporate Vice President, Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mr. Valeriani
◇◇————◇
Nicholas J. Valeriani
Board chair
◇◇————◇
Leslie S. Heisz
◇◇————◇
Ms. Heisz
◇◇————◇
Mr. LaViolette
◇◇————◇
Paul A. LaViolette
◇◇————◇
Mr. Gallahue
◇◇————◇
Kieran T. Gallahue
◇◇————◇
Ms. Sequeira
◇◇————◇
David T. Feinberg
◇◇————◇
Ramona Sequeira
◇◇————◇
Dr. Feinberg
◇◇————◇
Steven R. Loranger
◇◇————◇
Mr. Loranger
◇◇————◇
Ms. Davis
◇◇————◇
Leslie C. Davis
◇◇————◇
Bernard Zovighian served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Board meeting fee◇
Committee meeting fee◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Agilent Technologies, Inc. A
  • Align Technology, Inc. ALGN
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Boston Scientific Corporation BSX
  • DexCom, Inc. DXCM
  • GE Healthcare Technologies Inc. GEHC
  • Hologic, Inc. HOLX
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Intuitive Surgical, Inc. ISRG
  • Medtronic plc MDT
  • ResMed Inc. RMD
  • Stryker Corporation SYK
  • The Cooper Companies, Inc. COO
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 7, 2026=◇◇◇
2024May 8, 2025=◇◇◇
2023May 7, 2024=◇◇◇
2022May 11, 2023=◇◇◇
2021May 3, 2022=◇◇◇
2020May 4, 2021=◇◇◇
2019May 7, 2020=◇◇◇
2018May 8, 2019=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Bernard Zovighian (Chief Executive Officer and Director), FY2025 total compensation $17,454,255 (base salary $1,192,500) [exec_comp, SEC accession 0001099800-26-000015, filed 2026-03-26]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Edwards Lifesciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Edwards Lifesciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Edwards Lifesciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Edwards Lifesciences' disclosed peer group is defensible, who names Edwards Lifesciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
433 figures on this page: 424 cited to the filing that reported them, 9 calculated from figures it prints.
424 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001099800-26-000028
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001099800-26-000015
    CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Director Compensation Table – 2025 · and 3 more sections
  3. 0001099800-25-000026
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001099800-25-000013
    Summary Compensation Table - Fiscal Year 2022-2024
  5. 0001099800-24-000045
  6. 0001099800-24-000032
    Summary Compensation Table
  7. 0001193125-23-144564
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001099800-23-000013
    NAMED EXECUTIVE OFFICER COMPENSATION · Summary Compensation Table
  9. 0001193125-22-140622
  10. 0001193125-21-151848
  11. 0001193125-20-137597
  12. 0001193125-19-141632
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Edwards Lifesciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/EW (accessed 2026).
Short form: data: Velarion

The Edwards Lifesciences brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Edwards Lifesciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers Edwards Lifesciences discloses

The companies named in EW's own disclosed peer group.

Abbott LaboratoriesAgilent Technologies, Inc.Align Technology, Inc.Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationDexCom, Inc.GE Healthcare Technologies Inc.Hologic, Inc.IDEXX Laboratories, Inc.Illumina, Inc.Intuitive Surgical, Inc.Medtronic plcResMed Inc.Stryker CorporationThe Cooper Companies, Inc.Zimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy